Your arm position is worth 6.5 mmHg

LONGEVITY LATEST ISSUE 26 · 2 SEPTEMBER 2026

LONGEVITY LATEST

The Evidence-Based Edge on Living Longer and Better

Issue 26 · The Measurement Problem · 2 September 2026

WELCOME

👋 Welcome

Six and a half millimetres of mercury. That is what an unsupported arm adds to a systolic reading — and I promised you last week that the commonest measurement error happens before the cuff inflates. There it is. Not the device. The arm.

Blood pressure is the best-understood risk factor in medicine and the worst-measured one. That gap is the whole issue. Everything below either lowers the number or decides whether the number was ever real.

In this issue:

• 🔬 Top 3: the exercise that beat running, the salt that cut strokes in 20,995 people, and the first new drug class in four decades

• ⭐ Spotlight: home readings versus the clinic's — and the protocol that decides which one is right

• 🚨 Hype Check: the Class 3 rating your smartwatch doesn't mention

• 📖 Deep Dive: the peptides aimed at ageing itself — the follow-up to last week's tier list

THIS WEEK'S ANALYSIS

🔬 Top 3 Interventions Under the Microscope

Three interventions, ranked on nothing but how well the evidence holds. One costs about the same as salt. One costs fourteen minutes. One isn't licensed anywhere yet.

1. Potassium-enriched salt substitute — Evidence Grade: A

What it is. Ordinary table salt with a quarter to a third of the sodium chloride swapped for potassium chloride. Two levers at once: less sodium in, more potassium — which relaxes the vessel directly and tells the kidney to hold on to less sodium. Faintly metallic on its own, and nobody notices it in cooking.

Human evidence. SSaSS is the trial. 20,995 adults across 600 villages in rural China, cluster-randomised, mean follow-up 4.74 years, in people with a previous stroke or older age plus uncontrolled pressure. Stroke fell 14%, major cardiovascular events 13%, death from any cause 12%. Systolic pressure fell 3.3 mmHg.

Three point three millimetres. A later analysis attributed the outcome benefit almost wholly to that pressure drop rather than anything cleverer — which is why I find the hunt for the perfect supplement stack faintly comic.

Cautions. This is the one intervention here with a real way to hurt you. Potassium chloride is a problem if your kidneys clear potassium poorly: chronic kidney disease, or if you take an ACE inhibitor, an ARB, or a potassium-sparing diuretic such as spironolactone. SSaSS excluded people already taking potassium supplements. If any of that is you, get a potassium level before you switch, not after.

Takeaway. Grade A. Baseline sodium intake in that cohort was extraordinarily high, so the effect in a British kitchen is almost certainly smaller — but this is still the largest outcome trial of a dietary swap anyone has run, and the bag costs about £3.

2. Isometric exercise — Evidence Grade: B

I keep going back to this one because the number looks wrong.

What it is. Holding a contraction without moving — a wall sit, a plank, a handgrip squeeze. The proposed mechanism is a repeated cycle of restricted and then restored blood flow through the working muscle, which over weeks appears to change how the vessel lining handles pressure.

Human evidence. Edwards and colleagues, in the British Journal of Sports Medicine, pooled 270 randomised trials and 15,827 people. Aerobic training cut resting pressure by 4.49/2.53 mmHg. Dynamic resistance, 4.55/3.04. High-intensity intervals, 4.08/2.50. Isometric training, 8.24/4.00 — roughly double, and top of the network ranking with a SUCRA of 98.3% against running's 40.5%.

That sits in the range a single antihypertensive drug delivers, from fourteen minutes three times a week. Which ought to make you suspicious rather than excited.

Cautions. The isometric trials are small and short — a few dozen people over four to eight weeks — against decades of large aerobic trials, and a network ranking compares across studies rather than head to head. Holding a contraction while holding your breath spikes pressure acutely, which matters if you have an aortic aneurysm, proliferative retinopathy, or severely uncontrolled pressure. Breathe through it.

Takeaway. Grade B, and I wanted to go higher. The pooled effect is remarkable and the evidence underneath it is thin in precisely the way that produces regression to the mean. Do it anyway — four sets of two minutes against a wall, three times a week, is a cheap bet. Just don't stop walking.

3. Baxdrostat — Evidence Grade: B

What it is. An aldosterone synthase inhibitor. It blocks the enzyme that makes aldosterone rather than the receptor aldosterone lands on — spironolactone does the second thing, and brings gynaecomastia with it. The reason this took forty years is that the enzyme making aldosterone is a near-twin of the one making cortisol. Think of cutting one wire in a bundle where two are the same colour.

Human evidence. BaxHTN, phase 3, in the New England Journal last October: in uncontrolled and resistant hypertension already on standard care, 2 mg produced a placebo-adjusted systolic fall of 9.8 mmHg at twelve weeks. Bax24, in the Lancet this March, took only patients with true resistant hypertension and used ambulatory monitoring — 24-hour systolic down 16.9 mmHg, night-time down 11.7. Those are the largest ambulatory reductions any randomised trial has produced in resistant hypertension, according to the authors; nobody has run the head-to-head that would settle it.

Cautions. Hyperkalaemia again, and it will need monitoring. Cortisol suppression is the thing to watch as the numbers accumulate. And there is no outcomes trial: nobody has yet shown a stroke or a heart attack prevented, only a pressure moved.

Takeaway. Grade B — two good phase 3 trials, surrogate endpoints only, not licensed anywhere as I write. If the outcomes follow the pressure, it matters for roughly one hypertensive patient in ten, whose numbers won't come down on three drugs.

SPOTLIGHT

⭐ Spotlight: Home Readings Versus the Clinic's

Home readings do beat the clinic's. But the superiority belongs to the protocol, not the machine — and that one distinction decides whether the monitor in your drawer is worth owning.

Pros. Home measurement predicts cardiovascular events and death better than office measurement. Finn-Home, Ohasama and the pooled IDHOCO database of 6,887 people all converge on it: more readings, no observer bias, no white-coat effect. It also catches masked hypertension — normal at the surgery, high at home — which carries real risk and which the clinic cannot see, by definition.

Cons. IDHOCO's work on how many readings you need is unambiguous: the picture keeps sharpening through the first three to four days and roughly sixteen readings, and settles around day six. One reading, taken once, at whatever hour, after coffee, is not out-of-office monitoring.

A home monitor used casually is not a better measurement than the clinic's. It is a worse one, taken more often.

Ambulatory monitoring still wins on one axis neither of the others can touch. Night-time pressure is among the single best predictors of outcome in the literature, and a home cuff cannot measure you asleep.

Bottom line. ✅ Evidence supports use — with the protocol attached. Seven days, morning and evening, two readings a minute apart each time, discard day one entirely, average the rest. That average is what goes to your GP, not the worst number you saw. Biohacking Corner below has the sitting technique that makes each of those readings mean something.

HYPE CHECK

🚨 Hype Check: The Blood Pressure on Your Wrist

The Hype: Apple's hypertension notifications, Samsung's Galaxy Watch blood pressure feature, and a wave of cuffless rings from Oura and Whoop — £250 to £400, sold on the premise that a wrist can replace an inflating cuff.

The Evidence: Two things, worth keeping apart. What the bodies conclude: the 2025 AHA/ACC guideline gives cuffless devices a Class 3, No Benefit rating for diagnosing or managing hypertension, and an AHA scientific statement chaired by Jordana Cohen (Hypertension, 2026; 83:876–886) notes that FDA clearance does not require the clinical validation that would establish accuracy in real-world use. What the validation work shows: in the largest published study, systolic error was smallest in young, normotensive people and degraded substantially in older and hypertensive ones.

Why It's Misleading: This next part is my reading rather than a finding. Most cuffless devices are calibrated against a cuff, so they inherit that reading and then drift from it — which means a device tracking its own calibration rather than your arteries looks reassuringly steady while the thing it is meant to measure moves. If that is the mechanism, the accuracy pattern above is the problem in miniature: least reliable in exactly the group buying one to manage a diagnosis.

Our Verdict: Apple's notification feature is a screening prompt, and a decent one — its job is to tell you to go and buy a cuff. Past that, I wouldn't use any of them to make a decision. A validated upper-arm monitor is £30 to £40; check the model against the STRIDE BP or ESH validated lists first, because most of what ranks on Amazon isn't on either. One genuine exception: a handful of watches, Huawei's among them, use a real miniature inflating cuff in the strap rather than an optical guess. Different category, different argument.

SUPERFOOD

🥗 Superfood Spotlight: Beetroot, and the Bacteria on Your Tongue

Nitrate from vegetables is converted to nitrite by bacteria on the back of your tongue, and from there to nitric oxide, which relaxes the vessel wall. Your own nitric oxide production falls with age, which is why this matters more after sixty than before it.

Exeter's group (Vanhatalo and colleagues, Free Radical Biology and Medicine, 2025) gave 36 adults aged sixty-seven to seventy-nine two weeks of nitrate-rich beetroot shots against a nitrate-stripped placebo, crossover and double-masked. Pressure fell in that group and not in the 39 under-thirties tested alongside them. Two caveats worth carrying: a separate crossover in fifteen older adults already on treatment found no sustained benefit, and antibacterial mouthwash strips out the bacteria doing the conversion.

A beetroot costs about 60p and a bag of rocket £1.20. The shots run to £1.50 each, which is the expensive way to eat a vegetable.

DEEP DIVE

📖 Deep Dive: The Peptides Aimed at Ageing Itself

Change of subject, and a promise kept from last week.

The best evidence that any peptide slows human ageing comes from a trial that wasn't looking for it. A post-hoc analysis of a 32-week semaglutide trial, published in Nature Communications in May, ran seventeen DNA methylation clocks across 84 participants: PhenoAge down 4.9 years against placebo, PCGrimAge down 3.1, the pace-of-ageing measure about 9% slower.

Last week's tier list graded twenty-one peptides on what they are sold to do. This one asks which have been tested against ageing itself — and the answer rearranges the table. Five entries, each failing in a different way, which is the actual point of the article.

👉 Read the Deep Dive: The Peptides Aimed at Ageing Itself →

BIOHACKING CORNER

🌡 Biohacking Corner: How to Take a Reading That Means Something

The ARMS trial (Liu and colleagues, JAMA Internal Medicine, 2024) put 133 adults through three arm positions in randomised order. Arm resting in the lap added 3.9 mmHg to systolic. Arm hanging unsupported at the side added 6.5. Spread across a population, that is the difference between diagnosed and not for a very large number of people.

I re-ran my own after reading it and lost four points off my average — a humbling way to learn I'd been measuring badly for years. The Spotlight gave you the schedule. This is the sitting.

1. Arm supported on a desk, cuff at heart level. Not your lap, not hanging at your side. This is the whole section in one line.

2. Five minutes sitting first. Bladder empty, feet flat, back supported, and don't talk — talking alone is worth several points.

3. Cuff on bare skin, and check the size against your arm circumference. A cuff too small over-reads — the second commonest error, and far less discussed.

4. Two readings a minute apart, averaged. If they differ by more than about 5 mmHg, take a third and average all three.

5. Morning and evening for seven days. Throw away day one entirely — it runs high, almost always — and average the rest. That average is the number the Spotlight is talking about, and the only one worth showing anybody.

The caveat matters as much as the protocol: take the average to your doctor rather than acting on it. Home numbers are for informing a treatment decision, not making one.

READER PULSE

📊 Reader Pulse

Last week I asked whether you had ever bought a peptide. Nine per cent had, from a clinic on prescription; 14% from a website; 31% had come close; 46% said the issue settled it. That 14% is higher than I expected and lower than I feared — and several of you wrote to say it was the batch-testing figure that changed your mind, not the evidence tables.

This week, given the subject: when did you last have your blood pressure measured?

• “Within the last month.”

• “This year, at a GP or a pharmacy.”

• “Longer ago than I'd like to admit.”

• “I have no idea.”

Vote at longevitylatest.com/poll-26 — and if you have a cuff in a drawer somewhere, this is the week to find it.

CLOSING

🎯 Closing

If you keep one thing from this issue, keep this: the number has to be real before anything else about it matters. An arm in your lap can move you across a diagnostic line in either direction, and no salt substitute, wall squat or new drug class corrects for that. The most valuable intervention here costs nothing and happens in the thirty seconds before the cuff inflates.

Next week, biological age tests: which clocks are measuring something real, what a “two-year reversal” is actually worth, and why two of them run on the same blood sample can disagree by a decade.

Stay curious and stay healthy!

— Christian Thomsen, Editor

Longevity Latest is published weekly by FrontWave Media Ltd. The content is for educational purposes and does not constitute medical advice. Blood pressure medicines are prescription medicines and decisions about them belong with a clinician who knows your history. Do not start, stop or alter any prescribed medication, and do not act on home readings, without speaking to your doctor. Potassium-based salt substitutes are not safe for everyone: if you have chronic kidney disease, or take an ACE inhibitor, an angiotensin receptor blocker, a potassium-sparing diuretic or a potassium supplement, speak to your doctor or pharmacist before using one. Baxdrostat is not licensed for use in any jurisdiction at the time of writing. If you are pregnant or breastfeeding, or have kidney disease, diabetes or established cardiovascular disease, consult your physician before making any change.

© 2026 FrontWave Media Ltd · Longevity Latest